Synapse Open Synapse
Biology

Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical

GEN · · 3 min read

The latest collaboration will encompass six biologic preclinical programs. Five programs focus on treatments originating with a wholly owned SBP Group subsidiary, LaNova Medicines. The sixth comes from another SBP Group subsidiary, Beijing Tide Pharmaceutical.

Latest from GEN